TIDMRUA
RNS Number : 1594K
RUA Life Sciences PLC
30 December 2020
30 December 2020
RUA Life Sciences plc
(the "Company" or the "Group")
Results of General Meeting
Total Voting Rights
Director/PDMR Dealings
RUA Life Sciences plc (AIM: RUA), the holding company of a group
of medical device businesses focused on the exploitation of
Elast-Eon(TM), a long-term implantable biostable polymer, is
pleased to announce that at the General Meeting held earlier today,
all resolutions proposed were duly passed by shareholders.
Furthermore, as announced earlier today the Open Offer closed
for acceptances at 11.00 a.m. on 29 December 2020 with final valid
applications from Qualifying Shareholders in respect of 831,522
Open Offer Shares. Qualifying Shareholders who have validly applied
for Open Offer Shares have received their full Open Offer
Entitlement. Applications made under the Excess Application
Facility were oversubscribed and have been scaled back pro-rata
such that approximately 9.7 per cent. of the Excess Application is
satisfied.
Accordingly, the Company will raise a total of approximately
GBP7.0 million (before expenses) through the Placing, Subscription
and Open Offer and has thus issued and allotted 5,831,522 New
Ordinary Shares. An application has been made for the 5,831,522 New
Ordinary Shares to be admitted to trading on AIM, which is expected
to take place at 8.00 a.m. on 31 December 2020.
The net proceeds of the Placing, Subscription and Open Offer
will be used by the Company primarily to fund the acceleration of
the Group's surgical heart valve through to human trials, to
accelerate development of the Company's TAVI valve, to scale up the
Group's graft manufacture to meet anticipated demand and to allow
further investment in capital equipment to assist in the scale up
of the Group's capacity.
Following Admission, the Company's issued share capital will
comprise 22,184,797 Ordinary Shares, of which none are held in
treasury, and 4,832,778 Deferred Shares which carry no voting
rights. The above figure of 22,184,797 may be used by Shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the voting rights of the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Details of the proxy votes received on each resolution by the
Company's Registrar are set out below:
Resolution For & Against Withheld Total
Discretionary votes
cast
Number % Number % Number %
of votes of votes of votes
---------------------- ---------- ------ ---------- ----- ---------- ---- ----------
Allotment of
Ordinary Shares
1 for Fundraising 3,587,593 99.19 28,968 0.80 328 0.01 3,616,889
---------------------- ---------- ------ ---------- ----- ---------- ---- ----------
Pre-emption
2 rights Fundraising 3,587,593 99.19 28,968 0.80 328 0.01 3,616,889
---------------------- ---------- ------ ---------- ----- ---------- ---- ----------
Allotment of
Ordinary Shares,
3 general authority 3,587,593 99.19 28,968 0.80 328 0.01 3,616,889
---------------------- ---------- ------ ---------- ----- ---------- ---- ----------
Pre-emption
4 rights 3,586,593 99.16 28,968 0.80 1,328 0.04 3,616,889
---------------------- ---------- ------ ---------- ----- ---------- ---- ----------
Pre-emption
rights, acquisitions
and specified
5 investments 3,586,593 99.16 28,968 0.80 1,328 0.04 3,616,889
---------------------- ---------- ------ ---------- ----- ---------- ---- ----------
John Ely, a Non-Executive Director of the Company and Anthea
Berg, a Person Closely Associated with Geoffrey Berg, a
Non-Executive Director of the Company, have subscribed for New
Ordinary Shares through the Subscription as detailed below.
Director/PDMR Shares Acquired Total Holding* Percentage of
Enlarged Share
Capital*
John Ely 4,167 4,167 0.0%
---------------- --------------- ----------------
Geoffrey Berg** 8,333 25,018 0.1%
---------------- --------------- ----------------
* following Admission
** Application made in the name of Anthea Berg, wife of Geoffrey
Berg
Unless otherwise defined herein, capitalised terms used in this
announcement shall have the same meanings as defined in the
circular sent to Shareholders on 11 December 2020.
For more information please contact:
RUA Life Sciences plc
Bill Brown, Chairman Tel: +44 (0) 77 3071
David Richmond, CEO 8296
Tel: +44 (0) 78 9999
6400
Shore Capital (Nomad and Joint Broker)
Tom Griffiths/David Coaten Tel: +44 (0)20 7408
4080
Cenkos Securities plc (Joint Broker)
Russell Cook/Max Gould (Corporate Finance)
Michael Johnson (Sales) Tel: +44 (0) 20 7397
8900
About RUA Life Sciences plc
The RUA Life Sciences group was created in April 2020 when RUA
Life Sciences Plc (formerly known as AorTech International Plc)
acquired RUA Medical Devices Limited to create a fully formed
medical device business. RUA Life Sciences is the holding company
of the Group's four trading businesses, each exploiting the Group's
patented polymer technology.
Our vision is to improve the lives of millions of patients by
improving and enabling medical devices with Elast-Eon(TM), widely
accepted as being the most biostable of all long-term implantable
polyurethanes.
Whether it is licensing Elast-Eon(TM), manufacturing a device or
component or developing next generation medical devices, a RUA Life
Sciences business is pursuing our vision.
Elast-Eon(TM)'s biostability is comparable to silicone while
exhibiting excellent mechanical, blood contacting and flex-fatigue
properties. These polymers can be processed using conventional
thermoplastic extrusion and moulding techniques. With over 7
million implants and over 14 years of successful clinical use, the
Group's polymers are proven in long-term life enabling
applications.
The Group's four business units are:
RUA Medical : End-to-end contract developer and manufacturer
of medical devices and implantable fabric specialist.
RUA Biomaterials Licensor of Elast-Eon(TM) polymers to the medical
: device industry.
RUA Vascular Commercialisation of large bore polymer sealed
: grafts and soft tissue patches.
RUA Structural Development of tri leaflet polymeric heart valves.
Heart :
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------------------------------------------------------------------------------------
a. Name John Ely
--------------------------------------- -------------------------------------------
2 Reason for notification Acquisition of shares
--------------------------------------- -------------------------------------------
a. Position/Status Non-Executive Director
--------------------------------------- -------------------------------------------
b. Initial notification/ Initial notification
Amendment
--------------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------
a. Name RUA Life Sciences Plc
--------------------------------------- -------------------------------------------
b. LEI 213800BMVB22PVOJ9Z28
--------------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------------------
a. Description of Ordinary shares of 5p each
the financial
instrument, type
of instrument
ISIN: GB0033360586
Identification
Code
--------------------------------------- -------------------------------------------
b. Nature of the Share purchase
transaction
--------------------------------------- -------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
--------------------------------------- ---------------------
120p 4,167
--------------------- ---------------
d. Aggregated information
- Aggregated Volume n/a
- Price
--------------------------------------- -------------------------------------------
e. Date of the transaction 31 December 2020
--------------------------------------- -------------------------------------------
f. Place of the transaction London Stock Exchange
--------------------------------------- -------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------------------------------------------------------------------------------------
a. Name Anthea Berg, PCA with Geoffrey Berg
--------------------------------------- -------------------------------------------
2 Reason for notification Acquisition of shares
--------------------------------------- -------------------------------------------
a. Position/Status Wife of Non-Executive Director
--------------------------------------- -------------------------------------------
b. Initial notification/ Initial notification
Amendment
--------------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------
a. Name RUA Life Sciences Plc
--------------------------------------- -------------------------------------------
b. LEI 213800BMVB22PVOJ9Z28
--------------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------------------
a. Description of Ordinary shares of 1p each
the financial
instrument, type
of instrument
ISIN: GB0033360586
Identification
Code
--------------------------------------- -------------------------------------------
b. Nature of the Share purchase
transaction
--------------------------------------- -------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
--------------------------------------- ---------------------
120p 8,333
--------------------- ---------------
d. Aggregated information
- Aggregated Volume n/a
- Price
--------------------------------------- -------------------------------------------
e. Date of the transaction 31 December 2020
--------------------------------------- -------------------------------------------
f. Place of the transaction London Stock Exchange
--------------------------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
ROMEAFAEDDLEFFA
(END) Dow Jones Newswires
December 30, 2020 06:36 ET (11:36 GMT)
Aortech (LSE:AOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aortech (LSE:AOR)
Historical Stock Chart
From Apr 2023 to Apr 2024
